TRML - Tourmaline Bio Inc Debt to Book Capitalization Ratio

The visualization of Tourmaline Bio, Inc. (TRML) financial quotes on the GURU.Markets platform demonstrates the asset's dynamics, the success of which relies on the efficacy of the IL-6 inhibitor for cardiological and ophthalmological pathologies, as well as the runway volume, which stands at 0.00. The business focuses on developing immunotherapy to combat severe inflammation of the joints and thyroid gland. Currently, these innovative developments are undergoing the testing stage, forming the initial phase of the product life cycle.

To identify fundamental benchmarks in the financial statements of Tourmaline Bio, Inc. (TRML), investors must evaluate the structure's degree of financial stability. This metric measures the ratio of total liabilities to equity, and analyzing the historical debt-to-book capitalization ratio reveals the extent to which the biotech startup's development relies on borrowed funds in the absence of internal operating revenues and its dependence on venture capital.